The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Insights into the role of novel BTKis in the treatment landscape of R/R CLL
Danielle Brander, MD, Duke University School of Medicine, Durham, NC, discusses the integration of novel BTK inhibitors (BTKis), namely second-generation covalent BTKis such as zanubrutinib and acalabrutinib and the third-generation non-covalent BTKi pirtobrutinib, into the treatment landscape of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). For now, covalent BTKis are favored in patients who have not received prior BTKi therapy or who relapse after treatment with ibrutinib. Non-covalent BTKis are predominantly used after covalent BTKis or venetoclax-based therapy. Dr Brander highlights that further research is needed to better understand how to best sequence these agents in clinical practice. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
AbbVie: consultant, site PI clinical trial (grant paid to institution), 3rd party writing support for abstract or manuscript ArQule/Merck: site PI clinical trial (grant paid to institution) Ascentage: site PI clinical trial (grant paid to institution); ended 10/2021 with PI transition AstraZeneca/Acerta: site PI clinical trial (grant paid to institution); ended 1/2023 BeiGene: site PI clinical trial (grant paid to institution), 3rd party writing support for abstract or manuscript Catapult: site PI clinical trial (grant paid to institution) DTRM: site PI clinical trial (grant paid to institution), ended 4/2023 Genentech: consultant, site PI clinical trial (grant paid to institution) Juno/Celgene/BMS: site PI clinical trial (grant paid to institution) MEI Pharma: site PI clinical trial (grant paid to institution) ended 11/2021 NeWave: site PI clinical trial (grant paid to institution) Novartis: site PI clinical trial (grant paid to institution) ended 9/2021 Nurix: site PI clinical trial (grant paid to institution) Pharmacyclics: consultant, site PI clinical trial (grant paid to institution), 3rd party writing support for abstract or manuscript TG Therapeutics: site PI clinical trial (grant paid to institution), 3rd party writing support for abstract or manuscript; ended 4/2023 Other memberships (when sponsored or consultant also included under sponsor above): NCCN panel member CLL/SLL and HCL (unpaid), informCLL registry steering committee (Pharmacyclics), CORE registry steering committee (AbbVie), CLL Society (expert medical council unpaid), Alliance in Clinical Trials: Leukemia committee member & Trial Champion of S1925 (unpaid).
